Researchers in South India are investigating whether levels of selenoprotein P can serve as a biomarker for microvascular complications in individuals with type 2 diabetes mellitus. The study, conducted in Madras, India, focuses on the potential link between selenium levels and the development of diabetic kidney disease (DKD), a significant health concern for those with diabetes.
Type 2 diabetes affects over 400 million people globally and is a leading cause of DKD. The research aims to identify readily measurable indicators that can predict the progression of these complications, allowing for earlier intervention and improved patient outcomes. The study’s focus on selenoprotein P, a major selenium-containing protein in the blood, stems from previous research suggesting a connection between selenium deficiency and the severity of chronic pancreatitis and diabetes, particularly in tropical regions.
A study published in PubMed in 2009 examined selenium levels in patients with chronic pancreatitis and diabetes in Madras, comparing them to those in Manchester, England. The research concluded that while selenium levels decreased in patients from both locations, the decrement did not appear to be linked to the formation of pancreatic calculi or pancreatic exocrine failure, nor did it account for the accelerated progression to diabetes observed in tropical chronic pancreatitis. Though, the potential role of selenium and selenoproteins in diabetes continues to be explored.
Recent research, including a meta-analysis of observational studies, suggests a non-linear dose-response relationship between serum selenium levels and type 2 diabetes. This indicates that both very low and very high selenium levels may be associated with an increased risk of developing the condition. The investigation into selenoprotein P specifically seeks to determine if it can be used to assess this risk and predict the onset of microvascular complications.
The current study in South India is evaluating serum selenium levels in patients with uncomplicated diabetes mellitus. Researchers are analyzing data to determine if there is a correlation between selenoprotein P levels and the presence or severity of DKD. The findings could lead to the development of a simple blood test to identify individuals at higher risk of developing these complications, enabling more targeted preventative measures.
The research builds on earlier work examining selenium levels in patients with chronic pancreatitis and diabetes in India. The 2009 study found that selenium bioavailability was comparable between Indian and British patients, but the impact of selenium on the course of diabetes remained unclear. The current focus on selenoprotein P represents a refinement of this earlier research, aiming to pinpoint a specific biomarker for risk assessment.
The study’s findings are expected to contribute to a better understanding of the complex interplay between selenium, selenoproteins and the development of microvascular complications in type 2 diabetes. Further research is planned to validate these findings in larger and more diverse populations.
